IDEXX Laboratories, Inc. vs Texas Instruments Incorporated — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Texas Instruments Incorporated trades at $283.74 (market cap $263.20B). The key difference: Texas Instruments Incorporated is far larger — about 6.5× IDEXX Laboratories, Inc.'s market cap, and Texas Instruments Incorporated pays a 2.11% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Texas Instruments Incorporated for 76 Days on average.
| IDXX | TXN | |
|---|---|---|
Market Cap | $40.43B | $263.20B |
Volume | 692,164 | 5,850,256 |
Sector | Health | Technology |
52-Week High | $766.68 | $332.35 |
52-Week Low | $504.70 | $153.33 |
Typical Hold Time | 46 Days | 76 Days |
Enterprise Value | $41.32B | $270.25B |
Dividend Yield | — | 2.11% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding the $3.94 estimate. Revenue grew to $4.3 billion in 2025, and net income margin expanded to 25.03%. Recent acquisitions like CoVetAI aim to enhance veterinary workflow intelligence.
The outlook remains positive given robust profitability and analyst consensus, but risks include foreign exchange headwinds and competitive pressures. With a consensus price target of $665, representing ~30% upside, the stock offers growth potential for investors comfortable with its premium valuation multiples.
Texas Instruments (TXN) trades at $288.20, down 0.26% on the day, with strong technical momentum showing bullish moving averages and key support at $284. The company demonstrates robust fundamentals with 31.11% net margins and 34.97% ROE, though valuation ratios remain elevated with a P/E of 43.8. Recent earnings show mixed results with Q1 and Q2 2026 beats but a Q4 2025 miss, while data center sales growth and dividend payments highlight ongoing shareholder returns.
Outlook remains positive with analyst consensus targeting $325 (13% upside) amid accelerating revenue growth and AI-driven demand. Key risks include premium valuation sensitivity, cyclical semiconductor exposure, and rising debt levels. Institutional sentiment is bullish with 48% buy ratings, supported by strong cash flow generation and strategic positioning in industrial and data center markets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →